Search
for
Sort by
Research 961–990 of 1000+
- Safety and effectiveness of sacituzumab govitecan in patients with metastatic triple-negative breast cancer in real-world settings: first observations from an interdisciplinary breast cancer centre in Germany
- (Un)targeted Scanning of Locks of Hair for Drugs of Abuse by Direct Analysis in Real Time–High-Resolution Mass Spectrometry
- Finasteride versus dutasteride: a real-world economic evaluation.
- JAK Inhibitor Safety in Atopic Dermatitis and Alopecia Areata: A 4.5-Year Real-World Retrospective Cohort Study
- Large-Scale, Multicenter, Prospective Registry Study of Ripretinib in Advanced GIST: A Real-World Study from China
- A prospective real-world study evaluating serum levels of arginine and cysteine in women with chronic telogen effluvium: do we really need blanket prescription of amino acid supplementation?
- Efficacy assessment for low-level laser therapy in the treatment of androgenetic alopecia: a real-world study on 1383 patients
- Balding by 25: 5 Real Reasons Indian Men Are Losing Hair Decades Early (It's Not Just Genes)
- Balding by 25: 5 Real Reasons Indian Men Are Losing Hair Decades Early (It's Not Just Genes)
- Dermatologists’ Perspectives and Real-World Assessment of Alopecia Areata Severity, Burden, and Healthcare Resource Utilization in Adults in the United Arab Emirates
- Dermatologists’ Perspectives and Real-World Assessment of Alopecia Areata Severity, Burden, and Healthcare Resource Utilization in Adults in the Kingdom of Saudi Arabia
- 73571 The real-world impact of JAK inhibitor treatment on anxiety and depression outcomes and the role of eyebrow and eyelash hair regrowth in alopecia areata: TARGET-DERM
- Insights from real-world data: clinical features and treatment patterns of Compound Jinqiancao Granules in patients with prostatitis
- P151 A multicentre real-world evaluation of ritlecitinib in severe alopecia areata: patient-reported outcome measures
- Evaluating the safety profile of α-1 blockers, 5α-reductase inhibitors, and PDE5I for BPH: a disproportionality analysis of real-world adverse events based on FDA adverse event reporting system (FAERS)
- Pathological Insights into the Limitations of Clinical and Dermoscopic Evaluations in Monitoring Sonidegib Treatment Response for Locally Advanced Basal Cell Carcinoma: A Real-World Study
- Findings from the assessment of real-world disease characteristics and outcomes in alopecia areata in a global non-interventional observational cohort (ADAAGIO) study
- Clinical Trial Eligibility in Real‐World Alopecia Areata Patients Treated With Baricitinib
- A 52-Week Real-Life Study of Baricitinib in Moderate to Severe Alopecia Areata: Clinical, Trichoscopic Assessment and Patient Reported Outcomes
- Baricitinib Effectiveness and Patient Impressions in Routine Clinical Practice: 12-month Results from a Prospective Observational Real-world Study
- Baricitinib in Alopecia Areata: Real-Life Changes in Lipid Profile and Hematologic Inflammation Indices at 52 weeks
- Long‐Term Real‐World Outcomes of Baricitinib in Severe Alopecia Areata: A 104‐Week Retrospective Analysis From a Single Institute
- Effectiveness of baricitinib in severe alopecia areata in real life: a retrospective study of 87 patients
- EPH225 Dermatologists’ Perspectives and Real-World Assessment of Alopecia Areata Severity Among Adults in Taiwan
- SAT-560 Real or Not Real? An Elevated TSH
- Post‐finasteride syndrome: real or myth?
- P718 Observational real-world evidence on the efficacy and safety of Janus Kinase inhibitors (JAKi) in the treatment of moderate to severe Active Ulcerative Colitis (UC)
- 43696 Early real-world experience with baricitinib in the treatment of severe alopecia areata
- 44047 Long Term Real-World Treat-to-Target Skin Clearance and Maintenance of Response with Risankizumab in Patients with Moderate to Severe Psoriasis From the CorEvitas Psoriasis Registry
- 43364 Long Term Real-World Patient-Reported Outcomes with Risankizumab in Patients with Moderate to Severe Psoriasis From the CorEvitas Psoriasis Registry